[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644417":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":21,"responsibleParty":115,"collaborators":10,"id":119,"slug":120,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":10,"eligibilityCriteria":124,"healthyVolunteers":121,"sex":125,"minAge":126,"maxAge":10,"enrollmentInfo":127,"targetDuration":10,"studyType":130,"phases":10,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":103,"whyStopped":10,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"Beneficência Portuguesa de São Paulo","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Discovery cohort with cardiotoxicity",null,"This cohort will consist of participants with cardiotoxicity after one year of treatment and will be used for exome analysis and miRNA sequencing. In this cohort, metabolomic and proteomic profiling, drug concentration measurements, and assessments of immune function and inflammation will also be be performed.",{"label":13,"type":10,"description":14,"interventionNames":10},"Validation cohort with cardiotoxicity","This cohort will consist of participants with cardiotoxicity after one year of treatment and will be used to validate the genetic variants identified through exome analysis, as well as the miRNAs selected following sequencing.",{"label":16,"type":10,"description":17,"interventionNames":10},"Discovery cohort without cardiotoxicity","This cohort will consist of participants without cardiotoxicity after one year of treatment and will be used for exome analysis and miRNA sequencing. In this cohort, metabolomic and proteomic profiling, drug concentration measurements, and assessments of immune function and inflammation will also be be performed.",{"label":19,"type":10,"description":20,"interventionNames":10},"Validation cohort without cardiotoxicity","This cohort will consist of participants without cardiotoxicity after one year of treatment and will be used to validate the genetic variants identified through exome analysis, as well as the miRNAs selected following sequencing.",[22,42,57,72,87,101],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Instituto do Câncer do Ceará","NOT_YET_RECRUITING","Fortaleza","Ceará","60430-230","Brazil","BR",{"type":31,"coordinates":32},"Point",[33,34],-38.54306,-3.71722,{"lat":34,"lon":33},[37],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Flávio Silveira Bittencourt","CONTACT","+558532884576","flavio.bitencourt@icc.org.br",{"facility":43,"status":24,"city":44,"state":45,"zip":46,"country":28,"countryCode":29,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"Complexo Hospitar HUOC\u002FPROCAPE","Recife","Pernambuco","50100-130",{"type":31,"coordinates":48},[49,50],-34.88111,-8.05389,{"lat":50,"lon":49},[53],{"name":54,"role":39,"phone":55,"phoneExt":10,"email":56},"Maria Tereza Cartaxo Muniz","+5581982066802","tereza.cartaxo@upe.br",{"facility":58,"status":24,"city":59,"state":60,"zip":61,"country":28,"countryCode":29,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Universidade Federal de Santa Catarina","Florianópolis","Santa Catarina","88040-900",{"type":31,"coordinates":63},[64,65],-48.54917,-27.59667,{"lat":65,"lon":64},[68],{"name":69,"role":39,"phone":70,"phoneExt":10,"email":71},"Laureane Nunes Masi","+554830912289","laureane.masi@ufsc.br",{"facility":73,"status":24,"city":74,"state":75,"zip":76,"country":28,"countryCode":29,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Hospital Beneficente UNIMAR","Marília","São Paulo","17525-160",{"type":31,"coordinates":78},[79,80],-49.94583,-22.21389,{"lat":80,"lon":79},[83],{"name":84,"role":39,"phone":85,"phoneExt":10,"email":86},"Sandra Maria Barbalho","+5514996553190","smbarbalho@unimar.br",{"facility":88,"status":24,"city":89,"state":75,"zip":90,"country":28,"countryCode":29,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"FAMERP - Faculdade de Medicina de São José do Rio Preto","São José do Rio Preto","15090-000",{"type":31,"coordinates":92},[93,94],-49.37944,-20.81972,{"lat":94,"lon":93},[97],{"name":98,"role":39,"phone":99,"phoneExt":10,"email":100},"Marcelo Arruda Nakazone","+551732015054","marcelo.nakazone@edu.famerp.br",{"facility":102,"status":103,"city":75,"state":75,"zip":104,"country":28,"countryCode":29,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Hospital BP - A Beneficência Portuguesa de São Paulo","RECRUITING","01323-900",{"type":31,"coordinates":106},[107,108],-46.63611,-23.5475,{"lat":108,"lon":107},[111],{"name":112,"role":39,"phone":113,"phoneExt":10,"email":114},"Researcher Support and Incentive Center (NAIPE)","+55113505-1010","naipe@bp.org.br",{"type":116,"investigatorFullName":117,"investigatorTitle":118,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Mario Hiroyuki Hirata","Scientific Advisor, Professor, and Principal Investigator","100644417","development-of-a-pharmacogenomic-panel-for-early-detection-of-chemotherapy--and-immunotherapy-induced-cardiotoxicity-100644417",false,"NCT07663357","Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of breast cancer who are scheduled to initiate treatment with anthracyclines and\u002For HER2-targeted therapies (anti-HER2 therapies).\n\nExclusion Criteria:\n\n* Patients with a left ventricular ejection fraction (LVEF) \\\u003C 50%;\n* Patients who have undergone chemotherapy and\u002For radiotherapy within the previous year;\n* Patients with chronic kidney disease and a glomerular filtration rate (GFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m²;\n* Patients with uncontrolled hypertension;\n* Patients with complex congenital heart disease.","ALL","18 Years",{"count":128,"type":129},1000,"ESTIMATED","OBSERVATIONAL","To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.",[133],"Cardiotoxicity",[135,133,136,137],"oncology","pharmacogenomics","epigenomics","2026-06-17",{"date":140,"type":141},"2026-06-23","ACTUAL",{"date":143,"type":141},"2026-05-11",{"date":145,"type":129},"2029-12-30",{"name":5,"class":6},6]